arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BioAtla, Inc.

BCAB
$1.79 0.00 (0.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

BioAtla, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $3.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -0.5%
FCF / Share $-0.25
Trailing P/E 6.6x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 28, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$452.00K
↑ +107.1%
FCF / Share Free cash flow per share
$-0.25
↑ +92.8%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters